Loading patent…
AssigneeCantargia AB
InventorsHelena Ågerstam, Thoas Fioretos, Marcus Järås, Cecilia Ann-Christin Malmborg Hager, Kjell Sjöström, Agneta Svedberg, Karin von Wachenfeldt
Estimating the term…
The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting the binding of antibody ‘CAN04’ to human IL1RAP. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of IL-1 associated diseases and conditions, including cancers such as acute myeloid leukemia and melanoma.
An antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting the binding of reference antibody ‘CAN04’ to human IL1RAP.
An antibody or antigen-binding fragment thereof according to any one of the preceding claims wherein the antibody or antigen-binding fragment is capable of inducing ADCC of cells expressing IL1RAP.
An antibody or antigen-binding fragment thereof according to any one of the preceding claims wherein the antibody or antigen-binding fragment is capable of binding to an epitope on the extracellular domain of IL1RAP which overlaps, at least in part, with the epitope on IL1RAP to which antibody CAN04 is capable of binding.
An antibody or antigen-binding fragment thereof according to any one of the preceding claims wherein the epitope is located at or within amino acids 135 to 234 of IL1RAP.
An antibody or antigen-binding fragment thereof according to any one of the preceding claims comprising or consisting of an intact antibody.
An antibody or antigen-binding fragment thereof according to any one of the preceding claims comprising a heavy chain variable region comprising the following CDRs:
An antibody or antigen-binding fragment thereof according to any one of the preceding claims comprising a heavy chain variable region comprising the following CDRs:
An antibody or antigen-binding fragment thereof according to any one of the preceding claims comprising a light chain variable region comprising the following CDRs:
An antibody or antigen-binding fragment thereof according to any one of the preceding claims comprising a heavy chain variable region which comprises or consists of the amino acid sequence of any one of SEQ ID NOs:
An antibody or antigen-binding fragment thereof according to any one of the preceding claims comprising a heavy chain constant region, or part thereof.
An antibody or antigen-binding fragment thereof according to any one of the preceding claims comprising a light chain constant region, or part thereof.
An antibody or antigen-binding fragment thereof according to any one of the preceding claim comprising an Fc region.
An antibody or antigen-binding fragment thereof according to any one of the preceding claims lacking or low in fucose residues in the Fc region.
An antibody or antigen-binding fragment thereof according to any one of the preceding claims wherein the antibody or antigen-binding fragment thereof is capable of inhibiting IL1 signalling.
An antibody or antigen-binding fragment thereof according to any one of the preceding claims wherein the antibody or antigen-binding fragment thereof is capable of inhibiting IL33 signalling.
An antibody or antigen-binding fragment thereof according to any one of the preceding claims wherein the antibody or antigen-binding fragment thereof is capable of inhibiting IL36 signalling.
An antibody or antigen-binding fragment thereof according to any one of the preceding claim further comprising a moiety for increasing the in vivo half-life of the agent.
An antibody or antigen-binding fragment thereof according to any one of the preceding claim further comprising a cytotoxic moiety.
An antibody or antigen-binding fragment thereof according to any one of the preceding claims wherein the antibody polypeptide further comprises a detectable moiety.
An antibody or antigen-binding fragment thereof according to any one of the preceding claims wherein the antibody polypeptide comprises a pair of detectable and cytotoxic radionuclides, such as 86Y/90Y or 124I/211At.
An isolated nucleic acid molecule encoding an antibody or antigen-binding fragment thereof according to any one of the preceding claims or a component polypeptide chain thereof.
An antibody or antigen-binding fragment thereof, or use of the same, substantially as herein described with reference to the description.
Dependencies are inferred from the claim text.